Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 197 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prostate Hypertrophy Clear all
Completed No phase listed Observational Results available

Embosphere® PROstate Post Market Study

NCT03527589
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Prostate artery embolization
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 9, 2026, 5:00 AM EDT
Terminated Phase 2 Interventional Results available

A Study in Men With Benign Prostatic Hyperplasia

NCT01097707
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
LY500307, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendora, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00384930
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greenwood, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 9, 2026, 5:00 AM EDT
Recruiting Not applicable Interventional

Effect of Text Message Reminders on M-ISI Score After Prostate Surgery

NCT07071207
View directory record Official record
Conditions
Incontinence, Urinary Stress, Prostate Cancer, Benign Prostate Hyperplasia
Interventions
Text message reminders
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Not applicable Interventional Results available

UroLift System TOlerability and ReCovery When Administering Local Anesthesia

NCT01876706
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift® System
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
7
States / cities
San Diego, California • Daytona Beach, Florida • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 9, 2026, 5:00 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Office Based Transperineal Laser Ablation for Benign Prostatic Hyperplasia HYPERPLASIA

NCT04760483
View directory record Official record
Conditions
Male Urogenital Diseases, Genital Diseases, Male, Prostatic Disease, Prostatic Hyperplasia
Interventions
SoracteLite(TM) TPLA for BPH
Device
Lead sponsor
Urological Research Network, LLC
Other
Eligibility
40 Years to 85 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Not applicable Interventional

Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices

NCT02015806
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Breast Cancer, Depression, Mental Health Disorder, Prostatic Hypertrophy, Benign, Parkinson's Disease, Epilepsy
Interventions
RxTimerCap, Take-N-Slide, Pillbox
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
53,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Woonsocket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 2Phase 3 Interventional

MCS in the Treatment of Lower Urinary Tract Symptoms

NCT01002417
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo
Drug
Lead sponsor
Health Ever Bio-Tech Co., Ltd.
Industry
Eligibility
40 Years and older · Male only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 2 Interventional

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

NCT01939184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
WC3055, Placebo
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years and older · Male only
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
95
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

NCT00759135
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Interventions
2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years to 75 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 9, 2026, 5:00 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).

NCT00044226
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
ML-04A
Drug
Lead sponsor
Milkhaus Laboratory
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
14
States / cities
Mobile, Alabama • Fair Oaks, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions
Tadalafil, Placebo, Finasteride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Davis, California • Fresno, California • Laguna Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

NCT02184585
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 9, 2026, 5:00 AM EDT
Withdrawn No phase listed Observational

RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up

NCT05784558
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Watchful Waiting or BPH Medications, Other Surgical Intervention
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
45 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS

NCT01589263
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Interventions
onaBoNT-A + placebo, Tamsulosin + placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Not applicable Interventional Results available

The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects

NCT00710749
View directory record Official record
Conditions
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
Interventions
Disposable device, Digital device, Clinic flow measurement
Device
Lead sponsor
Wellspect HealthCare
Industry
Eligibility
45 Years to 85 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State

NCT00537654
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Not applicable Interventional Results available

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

NCT02505919
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
AQUABEAM System, Transurethral Resection of the Prostate (TURP)
Device · Procedure
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • La Mesa, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Not applicable Interventional

Early Apical Release vs Classic Holmium Laser Enucleation of the Prostate: Randomized Controlled Trial Comparing Post-Operative Incontinence Rates and Surgical Outcomes

NCT04566588
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
EAR HoLEP, Classic HoLEP
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 9, 2026, 5:00 AM EDT
Withdrawn Not applicable Interventional

Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres

NCT02679430
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Prostate Arterial Embolization
Device
Lead sponsor
Antonios Likourezos
Other
Eligibility
35 Years to 99 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 9, 2026, 5:00 AM EDT
Completed Not applicable Interventional

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

NCT02167919
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Microspheres
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 9, 2026, 5:00 AM EDT
Completed No phase listed Observational Results available

GreenLight XPS Laser System Retrospective Chart Review

NCT02139969
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
GreenLight XPS Laser System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Male only
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Mountain View, California • Atlanta, Georgia • Westland, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 9, 2026, 5:00 AM EDT
Active, not recruiting No phase listed Observational

Stone and Laser Therapies Post-Market Study (SALT)

NCT06982235
View directory record Official record
Conditions
Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
Interventions
Ureteroscope system, Laser system
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Phoenix, Arizona • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 9, 2026, 5:00 AM EDT